Ignite Creation Date:
2024-05-05 @ 12:00 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00206726
Status:
COMPLETED
Last Update Posted:
2016-08-29
First Post:
2005-09-19
Brief Title:
AlemtuzumabFludarabine for RelapsedRefractory B-cell Chronic Lymphocytic Leukemia B-CLL
Sponsor:
Genzyme a Sanofi Company
Organization:
Sanofi
Key Dates - Follows AllAPIJSON File Order
Start Date:
2005-05
Start Date Type:
None
Primary Completion Date:
2008-04
Primary Completion Date Type:
ACTUAL
Completion Date:
2008-04
Completion Date Type:
ACTUAL
First Submit Date:
2005-09-19
First Submit QC Date:
September 19 2005
Study First Post Date:
2005-09-21
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2011-01-13
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2016-07-27
Last Update Post Date:
2016-08-29
Last Update Post Date Type:
ESTIMATED